報價延遲最少15分鐘:2025/01/11 11:16 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.51 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.01/-2.12
|
|
企業價值
492.95M
|
| 資產負債 |
|
每股賬面淨值
6.08
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
90.24M
|
|
每股收益
1.96
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 11:16 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States. |